The US has already been unwittingly offered an elixir that could possibly ward off age-related ailments, including dementia - a vaccine designed to combat shingles, a painful condition triggered by the reactivation of the varicella zoster virus that was present in people who had chickenpox as children.
The current vaccine, Shingrix, has proven highly effective at reducing the risk of shingles and its complications like nerve pain. But recent research indicates it could also be having an anti-aging effect. Studies have shown a link between receiving the shot and lower rates of dementia diagnosis.
One such study found that those who had received the vaccine were 20% less likely to be diagnosed with dementia, with similar findings observed in natural experiments conducted in Wales and Australia. Another recent study revealed slower progression of the disease and fewer deaths among people already suffering from dementia following vaccination.
However, despite this promising evidence, financial support for further research has been limited. It appears that the anti-aging benefits of Shingrix remain unknown due to lack of funding for clinical trials - with experts struggling to secure investment in a new study designed to explore this potential benefit.
It is ironic that the development of shingles vaccine came about because pharmaceutical companies, philanthropic groups and national governments invested their time and resources into creating one. Now though money is drying up for further research which would allow these potential benefits to be explored fully.
The main barrier to getting more Americans to take this vaccine seems to be low vaccination rates among men, people from underrepresented or marginalized groups, as well as lower-income individuals. As the US enters an era of vaccine hesitancy even among older people - with a recent decline in flu and pneumonia vaccinations among seniors.
The current vaccine, Shingrix, has proven highly effective at reducing the risk of shingles and its complications like nerve pain. But recent research indicates it could also be having an anti-aging effect. Studies have shown a link between receiving the shot and lower rates of dementia diagnosis.
One such study found that those who had received the vaccine were 20% less likely to be diagnosed with dementia, with similar findings observed in natural experiments conducted in Wales and Australia. Another recent study revealed slower progression of the disease and fewer deaths among people already suffering from dementia following vaccination.
However, despite this promising evidence, financial support for further research has been limited. It appears that the anti-aging benefits of Shingrix remain unknown due to lack of funding for clinical trials - with experts struggling to secure investment in a new study designed to explore this potential benefit.
It is ironic that the development of shingles vaccine came about because pharmaceutical companies, philanthropic groups and national governments invested their time and resources into creating one. Now though money is drying up for further research which would allow these potential benefits to be explored fully.
The main barrier to getting more Americans to take this vaccine seems to be low vaccination rates among men, people from underrepresented or marginalized groups, as well as lower-income individuals. As the US enters an era of vaccine hesitancy even among older people - with a recent decline in flu and pneumonia vaccinations among seniors.